The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
HER2 expression status in diverse cancers: review of results from 37,992 patients
Open accessAbstract
Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been reported in other malignancies, previous studies generally focused on one cancer type, making it challenging to compare HER2 positivity across studies/malignancies. Herein, we examined 37,992 patient samples for HER2 expression (+/- amplification) in a single laboratory. All 37,992 patients were tested by immunohistochemistry (IHC); 21,642 of them were also examined for HER2 amplification with either fluorescent in situ hybridization (FISH) (11,670 patients) or chromogenic in situ hybridization (CISH) (9,972 patients); 18,262 patients had tumors other than breast or gastric cancer. All tissues were analyzed in a Clinical Laboratory Improvement Amendments (CLIA) laboratory (Caris Life Sciences) at the request of referring physicians. HER2 protein overexpression was found in 2.7 % of samples. Over-expressed HER2 was detected predominantly in malignancies of epithelial origin; for cancers derived from mesenchyme, neuroendocrine tissue, central nervous system, and kidney, HER2 expression and amplification were remarkably rare or non-existent. Bladder carcinomas, gallbladder, extrahepatic cholangiocarcinomas, cervical, uterine, and testicular cancers showed HER2 positivity rates of 12.4, 9.8, 6.3, 3.9, 3.0, and 2.4 %, respectively. HER2 overexpression and/or amplification is frequently found across tumor types. These observations may have significant therapeutic implications in cancers not traditionally thought to benefit from anti-HER2 therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 613
HER2 testing in gastric cancer: a practical approach
Rüschoff, J., Hanna, W., Bilous, M., Hofmann, M., Osamura, R. Y., Penault-Llorca, F., van de Vijver, M., & Viale, G. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.198 · Cited by 595
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A.-M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 539
Self-citationSauter, G., Lee, J., Bartlett, J. M. S., Slamon, D. J., & Press, M. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8197 · Cited by 509
Rüschoff, J., Dietel, M., Baretton, G., Arbogast, S., Walch, A., Monges, G., Chenard, M.-P., Penault-Llorca, F., Nagelmeier, I., Schlake, W., et al. (2010) · Virchows Archiv · doi:10.1007/s00428-010-0952-2 · Cited by 486
Yoshikawa, D., Ojima, H., Iwasaki, M., Hiraoka, N., Kosuge, T., Kasai, S., Hirohashi, S., & Shibata, T. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604129 · Cited by 404
Insights from transgenic mouse models of ERBB2-induced breast cancer
Ursini-Siegel, J., Schade, B., Cardiff, R. D., & Muller, W. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2127 · Cited by 269
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
Janku, F., Hong, D. S., Fu, S., Piha-Paul, S. A., Naing, A., Falchook, G. S., Tsimberidou, A. M., Stepanek, V. M., Moulder, S. L., Lee, J. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.035 · Cited by 237
Self-citationLaé, M., Couturier, J., Oudard, S., Radvanyi, F., Beuzeboc, P., & Vieillefond, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp488 · Cited by 226
HER2 Mutation and Response to Trastuzumab Therapy in Non–Small-Cell Lung Cancer
Cappuzzo, F., Bemis, L., & Varella-Garcia, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmc060020 · Cited by 216
Heinrich, M. C., Joensuu, H., Demetri, G. D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4575 · Cited by 213
HER2 aberrations in cancer: Implications for therapy
Yan, M., Parker, B. A., Schwab, R., & Kurzrock, R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.008 · Cited by 210
Self-citationSeo, A. N., Kwak, Y., Kim, D.-W., Kang, S.-B., Choe, G., Kim, W. H., & Lee, H. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098528 · Cited by 175
HER2/neu testing in primary colorectal carcinoma
Ingold Heppner, B., Behrens, H.-M., Balschun, K., Haag, J., Krüger, S., Becker, T., & Röcken, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.483 · Cited by 169
HER2 testing: Current status and future directions
Perez, E. A., Cortés, J., Gonzalez-Angulo, A. M., & Bartlett, J. M. S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.001 · Cited by 161
HER 2/neu protein expression in colorectal cancer
Schuell, B., Gruenberger, T., Scheithauer, W., Zielinski, C. C., & Wrba, F. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-123 · Cited by 147
Williams, M. D., Roberts, D. B., Kies, M. S., Mao, L., Weber, R. S., & El‐Naggar, A. K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0238 · Cited by 146
Chmielecki, J., Ross, J. S., Wang, K., Frampton, G. M., Palmer, G. A., Ali, S. M., Palma, N. A., Morosini, D., Miller, V. A., Yelensky, R., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0234 · Cited by 113
Nardi, V., Sadow, P. M., Juric, D., Zhao, S. D., Cosper, A. K., Bergethon, K. E., Scialabba, V. L., Batten, J. M., Borger, D. R., Iafrate, A. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1842 · Cited by 113
Roa, I., de Toro, G., Schalper, K. A., de Aretxabala, X., Churi, C. R., & Javle, M. M. (2014) · Europe PMC (PubMed Central) · Cited by 103
Gown, A. M., Goldstein, L. C., Barry, T. S., Kussick, S. J., Kandalaft, P. L., Kim, P. M., & Tse, C. C. H. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.83 · Cited by 100
Perez, E. A., Press, M. F., Dueck, A. C., Jenkins, R. B., Kim, C., Chen, B., Villalobos, I. E., Paik, S., Buyse, M. E., Wiktor, A. E., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2444-y · Cited by 83
HER2 expression in cervical cancer as a potential therapeutic target
Chávez-Blanco, A. D., Pérez-Sánchez, V. M., González‐Fierro, A., Vela-Chávez, T., Candelaria, M., Cetina, L., Vidal, S., & Dueñas‐González, A. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-59 · Cited by 69
Galsky, M. D., Hoff, D. D. V., Neubauer, M., Anderson, T., Fleming, M. T., Nagarwala, Y. M., Mahoney, J. M., Midwinter, D., Vocila, L., & Zaks, T. Z. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9541-0 · Cited by 68
Wang, T., Hsieh, E., Henry, P., Hanna, W. M., Streutker, C., & Grin, A. (2014) · Human Pathology · doi:10.1016/j.humpath.2013.12.010 · Cited by 55
Falchook, G. S., Jankú, F., Tsao, A. S., Bastida, C. C., Stewart, D. J., & Kurzrock, R. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ce38e · Cited by 31
Self-citationHER2 Mutations in Non–Small-Cell Lung Cancer Can Be Continually Targeted
Kelly, R. J., Carter, C. A., & Giaccone, G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4902 · Cited by 27
Cited by
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,099
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.-Y., Banerjee, S., González-Martín, A., Jung, K. H., Ługowska, I., Manso, L., Manzano, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02005 · Cited by 1,069
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Metadata
- Authors
- Yan, M., Schwaederle, M., Arguello, D., Millis, S. Z., Gatalica, Z., & Kurzrock, R.
- Venue
- Cancer and Metastasis Reviews
- Published
- 2015-02-25
- Volume
- 34
- Issue
- 1
- Pages
- 157-164
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W2064394610
- Cited by
- 483
- References
- 39
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.